OBJECTIVE: The serine protease thrombin can dramatically alter endothelial gene expression in a manner that confers a proinflammatory phenotype. Recent studies have identified the Kruppel-like factor 2 (KLF2) as a critical regulator of endothelial gene expression. Herein, we provide evidence that KLF2 inhibits thrombin-mediated endothelial activation via alterations in expression of its principal receptor protease-activated receptor-1 (PAR-1). METHODS AND RESULTS: Forced expression of KLF2 in human umbilical vein endothelial cells potently inhibited the ability of thrombin to induce multiple prothrombotic factors (tissue factor, CD40L, plasminogen activator inhibitor-1), cytokines/chemokines (eg, monocyte chemotactic protein-1, interleukin-6 [IL-6], IL-8), and matrix degrading enzymes (eg, matrix metalloproteinases 1, 2, and 9). Mechanistically, KLF2 inhibits PAR-1 expression and, as a consequence, thrombin-mediated nuclear factor kappaB (NF-kappaB) nuclear accumulation and DNA binding. Conversely, small interfering RNA-mediated knockdown of KLF2 increases PAR-1 expression and thrombin-mediated induction of NF-kappaB activation. CONCLUSIONS: These studies identify KLF2 as a novel regulator of PAR-1 expression and thrombin action in endothelial cells.
OBJECTIVE: The serine protease thrombin can dramatically alter endothelial gene expression in a manner that confers a proinflammatory phenotype. Recent studies have identified the Kruppel-like factor 2 (KLF2) as a critical regulator of endothelial gene expression. Herein, we provide evidence that KLF2 inhibits thrombin-mediated endothelial activation via alterations in expression of its principal receptor protease-activated receptor-1 (PAR-1). METHODS AND RESULTS: Forced expression of KLF2 in human umbilical vein endothelial cells potently inhibited the ability of thrombin to induce multiple prothrombotic factors (tissue factor, CD40L, plasminogen activator inhibitor-1), cytokines/chemokines (eg, monocyte chemotactic protein-1, interleukin-6 [IL-6], IL-8), and matrix degrading enzymes (eg, matrix metalloproteinases 1, 2, and 9). Mechanistically, KLF2 inhibits PAR-1 expression and, as a consequence, thrombin-mediated nuclear factor kappaB (NF-kappaB) nuclear accumulation and DNA binding. Conversely, small interfering RNA-mediated knockdown of KLF2 increases PAR-1 expression and thrombin-mediated induction of NF-kappaB activation. CONCLUSIONS: These studies identify KLF2 as a novel regulator of PAR-1 expression and thrombin action in endothelial cells.
Authors: Jerry B Lingrel; Robyn Pilcher-Roberts; Joshua E Basford; Palanikumar Manoharan; Jon Neumann; Eddy S Konaniah; Ramprasad Srinivasan; Vladimir Y Bogdanov; David Y Hui Journal: Circ Res Date: 2012-04-03 Impact factor: 17.367
Authors: Ganapati H Mahabeleshwar; Daiji Kawanami; Nikunj Sharma; Yoichi Takami; Guangjin Zhou; Hong Shi; Lalitha Nayak; Darwin Jeyaraj; Robert Grealy; Mary White; Ross McManus; Thomas Ryan; Patrick Leahy; Zhiyong Lin; Saptarsi M Haldar; G Brandon Atkins; Hector R Wong; Jerry B Lingrel; Mukesh K Jain Journal: Immunity Date: 2011-05-12 Impact factor: 31.745
Authors: Paul R Clark; Todd J Jensen; Martin S Kluger; Maurice Morelock; Adedayo Hanidu; Zhenhao Qi; Revati J Tatake; Jordan S Pober Journal: Microcirculation Date: 2011-02 Impact factor: 2.628
Authors: Daiji Kawanami; Ganapati H Mahabeleshwar; Zhiyong Lin; G Brandon Atkins; Anne Hamik; Saptarsi M Haldar; Koji Maemura; Joseph C Lamanna; Mukesh K Jain Journal: J Biol Chem Date: 2009-06-01 Impact factor: 5.157